Quratis submitted a preliminary review as a technology special listed company on KOSDAQ

Quratis announced on the 17th that has submitted a preliminary review to the Korea Exchange(KRX) to be listed on KOSDAQ.

Last year, Quratis received A and A ratings in the technical evaluation from two professional institutes in order to be listed as a technology special listed companies on KOSDAQ.

Quratis, a professional bio-tech company that has secured new patent technologies that are more advanced than existing technologies in cooperation with leading domestic and foreign research institutes, and has been under the spotlight of the industry as it has focused on this market in the absence of tuberculosis vaccines for teenagers and adults in the world.

WHO warned that tuberculosis is the number one disease that threatens humanity, beating cancer. According to medical statistics, tuberculosis is the most life-threatening infectious disease in the world, and the incidence of tuberculosis in South Korea has been on the rise since adolescence, when immunization of tuberculosis vaccinations that was injected infants and toddlers age is falling.

In addition, South Korea has a stigma that it is overwhelmingly ranked first in the incidence, prevalence and mortality rates of tuberculosis among OECD countries, and it is a time when national management is in dire need of preventive measures, not treatment after the outbreak

Quratis's tuberculosis vaccine is adolescent and adult tuberculosis vaccine and has most commercially close in the world.